More information on Recordati’s new Cushing’s drug Isturisa

In a recent press release, Recordati Rare Diseases announced the results from a Phase III study of Isturisa® (Osilodrostat) published in Lancet Diabetes and Endocrinology.

“The exciting data, published today, underscore the efficacy and safety of ISTURISA in a prospective setting, and represent a significant advance for the management of patients with Cushing’s disease, a serious and potentially life-threatening rare condition,” said Rosario Pivonello, MD, Professor of Endocrinology at the Federico II University of Naples, Italy. “I would like to thank all the patients who participated in the LINC-3 study, and their families, who have helped to bring this new and welcome treatment option to this underserved patient population.”

Decreases in mUFC (mean urinary free cortisol) levels during treatment with ISTURISA were accompanied by improvements in clinical signs and cardiovascular-related risk factors (weight, BMI, blood glucose, blood pressure, and total cholesterol). ISTURISA® is well tolerated, with the most common adverse effects in LINC-3 being nausea (42%), headache (34%), fatigue (28%), and adrenal insufficiency (28%), according to the press release.

To read the press release and for more information on the phase III study and Isturisa®, click here.  

About the Lancet:  The Lancet began as an independent, international weekly general medical journal founded in 1823. Since its first issue (October 5, 1823), the journal has strived to make science widely available so that medicine can serve, and transform society, and positively impact the lives of people.


© 2020, Pituitary World News. All rights reserved.